Curis reports net income of $4.8M for first-quarter 2010: MicroStockProfit.com

NewsGuard 100/100 Score

MicroStockProfit.com announces an investment report featuring Curis Inc. (Nasdaq:CRIS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/CRIS

Curis Inc. (CRIS), a drug discovery and development company, focuses on the research and development of cancer therapeutics. The Company conducts its research programs both internally and through strategic collaborations. The Company, under collaboration with Genentech Inc., is conducting a pivotal phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various phase II clinical trials in first-line metastatic colorectal cancer and advanced ovarian cancer patients. In addition, CRIS has a development candidate, Debio 0932, which is a Heat Shock Protein 90 or Hsp90 inhibitor. The Company holds a license agreement with Debiopharm related to its Hsp90 technologies. Further, it engages in preclinical testing for the development of candidates from its targeted cancer programs.

Message Board Search for CRIS: http://www.boardcentral.com/boards/CRIS

In the report, the analyst notes:

"For the first quarter of 2010, CRIS reported net income of $4.8 million, or $0.07 per basic share outstanding and $0.06 per fully diluted share outstanding, as compared to net income of $1.1 million or $0.02 per share on both a basic and fully diluted share outstanding basis for the same period in 2009.

"… Reuters reported that two analysts including Benjamin remained optimistic about the drug's technology and said any weakness in the stock should be viewed as a buying opportunity. Benjamin has a "Market Outperform" rating and a price target of $6 on CRIS. Another analyst, Roth Capital Partners' Joseph Pantginis, kept his "Buy" rating on the stock but cut his price target to $3.50 from $4.50, expecting a 20% chance for the drug's success in treating ovarian cancer."

SOURCE MicroStockProfit.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Study reveals over 134,000 missed cancer diagnoses in the U.S. during COVID-19 pandemic